Refine
Language
- English (295)
Has Fulltext
- yes (295)
Is part of the Bibliography
- no (295)
Keywords
- Heavy Ion Experiments (5)
- Hadron-Hadron scattering (experiments) (2)
- Heavy-ion collision (2)
- ALICE detector (1)
- Anti-nuclei (1)
- COVID-19 (1)
- Centrality Class (1)
- Centrality Selection (1)
- Electron-pion identification (1)
- Fibre/foam sandwich radiator (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- LHC (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-wire proportional drift chamber (1)
- NMR spectroscopy (1)
- Neural network (1)
- Pb–Pb collisions (1)
- Production Cross Section (1)
- Rapidity Range (1)
- Resolution Parameter (1)
- SARS-CoV-2 (1)
- Systematic Uncertainty (1)
- TR (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Trigger (1)
- Xenon-based gas mixture (1)
- accessory proteins (1)
- cell-free protein synthesis (1)
- dE/dx (1)
- heavy ion experiments (1)
- intrinsically disordered region (1)
- nonstructural proteins (1)
- quark gluon plasma (1)
- structural proteins (1)
Institute
- Physik (293)
- Frankfurt Institute for Advanced Studies (FIAS) (274)
- Informatik (261)
- Hochschulrechenzentrum (2)
- Biochemie, Chemie und Pharmazie (1)
- Medizin (1)
The pseudorapidity (η) and transverse-momentum (pT) distributions of charged particles produced in proton-proton collisions are measured at the centre-of-mass energy s√ = 13 TeV. The pseudorapidity distribution in |η|< 1.8 is reported for inelastic events and for events with at least one charged particle in |η|< 1. The pseudorapidity density of charged particles produced in the pseudorapidity region |η|< 0.5 is 5.31 ± 0.18 and 6.46 ± 0.19 for the two event classes, respectively. The transverse-momentum distribution of charged particles is measured in the range 0.15 < pT < 20 GeV/c and |η|< 0.8 for events with at least one charged particle in |η|< 1. The correlation between transverse momentum and particle multiplicity is also investigated by studying the evolution of the spectra with event multiplicity. The results are compared with calculations from PYTHIA and EPOS Monte Carlo generators.
The pseudorapidity (η) and transverse-momentum (pT) distributions of charged particles produced in proton–proton collisions are measured at the centre-of-mass energy √s=13 TeV. The pseudorapidity distribution in |η|<1.8 is reported for inelastic events and for events with at least one charged particle in |η|<1. The pseudorapidity density of charged particles produced in the pseudorapidity region |η|<0.5 is 5.31±0.18 and 6.46±0.19 for the two event classes, respectively. The transverse-momentum distribution of charged particles is measured in the range 0.15<pT<20 GeV/c and |η|<0.8 for events with at least one charged particle in |η|<1. The evolution of the transverse momentum spectra of charged particles is also investigated as a function of event multiplicity. The results are compared with calculations from PYTHIA and EPOS Monte Carlo generators.
Direct photon production at mid-rapidity in Pb–Pb collisions at √sNN=2.76 TeV was studied in the transverse momentum range 0.9<pT<14 GeV/c. Photons were detected with the highly segmented electromagnetic calorimeter PHOS and via conversions in the ALICE detector material with the e+e− pair reconstructed in the central tracking system. The results of the two methods were combined and direct photon spectra were measured for the 0–20%, 20–40%, and 40–80% centrality classes. For all three classes, agreement was found with perturbative QCD calculations for pT≳5 GeV/c. Direct photon spectra down to pT≈1 GeV/c could be extracted for the 20–40% and 0–20% centrality classes. The significance of the direct photon signal for 0.9<pT<2.1 GeV/c is 2.6σ for the 0–20% class. The spectrum in this pT range and centrality class can be described by an exponential with an inverse slope parameter of (297±12stat±41syst) MeV. State-of-the-art models for photon production in heavy-ion collisions agree with the data within uncertainties.
The highly infectious disease COVID-19 caused by the Betacoronavirus SARS-CoV-2 poses a severe threat to humanity and demands the redirection of scientific efforts and criteria to organized research projects. The international COVID19-NMR consortium seeks to provide such new approaches by gathering scientific expertise worldwide. In particular, making available viral proteins and RNAs will pave the way to understanding the SARS-CoV-2 molecular components in detail. The research in COVID19-NMR and the resources provided through the consortium are fully disclosed to accelerate access and exploitation. NMR investigations of the viral molecular components are designated to provide the essential basis for further work, including macromolecular interaction studies and high-throughput drug screening. Here, we present the extensive catalog of a holistic SARS-CoV-2 protein preparation approach based on the consortium’s collective efforts. We provide protocols for the large-scale production of more than 80% of all SARS-CoV-2 proteins or essential parts of them. Several of the proteins were produced in more than one laboratory, demonstrating the high interoperability between NMR groups worldwide. For the majority of proteins, we can produce isotope-labeled samples of HSQC-grade. Together with several NMR chemical shift assignments made publicly available on covid19-nmr.com, we here provide highly valuable resources for the production of SARS-CoV-2 proteins in isotope-labeled form.
Aims: History of bleeding strongly influences decisions for anticoagulation in atrial fibrillation (AF). We analyzed outcomes in relation to history of bleeding and randomization in ARISTOTLE trial patients.
Methods and results: The on-treatment safety population included 18,140 patients receiving at least 1 dose of study drug (apixaban) or warfarin. Centrally adjudicated outcomes in relation to bleeding history were analyzed using a Cox proportional hazards model adjusted for randomized treatment and established risk factors. Efficacy end points were analyzed on the randomized (intention to treat) population. A bleeding history was reported at baseline in 3,033 patients (16.7%), who more often were male, with a history of prior stroke/transient ischemic attack/systemic embolism and diabetes; higher CHADS2 scores, age, and body weight; and lower creatinine clearance and mean systolic blood pressure. Major (but not intracranial) bleeding occurred more frequently in patients with versus without a history of bleeding (adjusted hazard ratio 1.35, 95% CI 1.14-1.61). There were no significant interactions between bleeding history and treatment for stroke/systemic embolism, hemorrhagic stroke, death, or major bleeding, with fewer outcomes with apixaban versus warfarin for all of these outcomes independent of the presence/absence of a bleeding history.
Conclusion: In patients with AF in a randomized clinical trial of oral anticoagulants, a history of bleeding is associated with several risk factors for stroke and portends a higher risk of major—but not intracranial—bleeding, during anticoagulation. However, the beneficial effects of apixaban over warfarin for stroke, hemorrhagic stroke, death, or major bleeding remains consistent regardless of history of bleeding.